Trial · NCT05941845
Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy
NCT05941845, Phase 2, Terminated, Centre Hospitalier Universitaire de Nice
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy. Trials, record NCT05941845. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05941845
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy
- NCT number
- NCT05941845
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- Centre Hospitalier Universitaire de Nice
- Conditions
- Membranous Nephropathy
- Interventions
- Peginterferon Alfa-2A 180 MCG/ML Injectable Solution
- First posted
- 2023-07-12
- Last updated
- 2026-06-18
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Membranous nephropathy immunological activity monitoring over 6-month interferon alfa treatment | 18 months | Intra-individual variation in anti-PLA2R1 antibody titer (ELISA titer in RU/mL), before and after 6 months of treatment with IFN alfa |
| Secondary | Nephrotic syndrome monitoring over 6-month interferon alfa treatment | Baseline to Week 24 | Intra-individual variation in proteinuria (g/g) under IFN alfa and stable symptomatic treatment |
| Secondary | Nephrotic syndrome monitoring over 6-month interferon alfa treatment | Baseline to Week 24 | Intra-individual variation in albuminemia (g/L) under IFN alfa and stable symptomatic treatment |
| Secondary | Immune response monitoring over 6-month interferon alfa treatment | Baseline to Week 24 | Intra-individual variation in cytokine profile (assay of 8 cytokines in pg/ml: IL-12p70; IL-17A; IL-4; IL-5; IL-1β; IL-10; IFNα; IL-6) before and after 6 months of personalized treatment with IFN alfa |
| Secondary | Immune response monitoring over 6-month interferon alfa treatment | Baseline to Week 24 | Intra-individual variation in cytokine profile (assay of 1 cytokine in UI/ml: IFNγ) before and after 6 months of personalized treatment with IFN alfa |
| Secondary | Clinical Tolerance monitoring over 6-month interferon alfa treatment | At Week 52 | Percentage of Participants with clinical Adverse Events (AEs) |
| Secondary | Biological Tolerance monitoring over 6-month interferon alfa treatment | At Week 52 | Percentage of Participants with biological Adverse Events (AEs) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05941845
GET https://conductscience.org/api/trials/v1/NCT05941845/registered